PL3362480T3 - Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie - Google Patents

Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie

Info

Publication number
PL3362480T3
PL3362480T3 PL16873228T PL16873228T PL3362480T3 PL 3362480 T3 PL3362480 T3 PL 3362480T3 PL 16873228 T PL16873228 T PL 16873228T PL 16873228 T PL16873228 T PL 16873228T PL 3362480 T3 PL3362480 T3 PL 3362480T3
Authority
PL
Poland
Prior art keywords
erbb3
specifically binding
antibody specifically
antibody
binding
Prior art date
Application number
PL16873228T
Other languages
English (en)
Inventor
Dong Goo Bae
Mi Young Kim
Young Mi Hur
Mi Rim HONG
Original Assignee
Isu Abxis Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59013461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3362480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isu Abxis Co., Ltd. filed Critical Isu Abxis Co., Ltd.
Publication of PL3362480T3 publication Critical patent/PL3362480T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16873228T 2015-12-07 2016-11-02 Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie PL3362480T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150173281A KR101746152B1 (ko) 2015-12-07 2015-12-07 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
EP16873228.7A EP3362480B1 (en) 2015-12-07 2016-11-02 Antibody specifically binding to erbb3 and use thereof
PCT/KR2016/012545 WO2017099362A1 (en) 2015-12-07 2016-11-02 Antibody specifically binding to erbb3 and use thereof

Publications (1)

Publication Number Publication Date
PL3362480T3 true PL3362480T3 (pl) 2022-01-03

Family

ID=59013461

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16873228T PL3362480T3 (pl) 2015-12-07 2016-11-02 Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie

Country Status (14)

Country Link
US (1) US10413607B2 (pl)
EP (2) EP3362480B1 (pl)
JP (2) JP6982574B2 (pl)
KR (1) KR101746152B1 (pl)
CN (2) CN112472804B (pl)
AR (1) AR107012A1 (pl)
AU (1) AU2016365506B2 (pl)
CA (1) CA3000835C (pl)
ES (1) ES2891990T3 (pl)
MX (1) MX394911B (pl)
PL (1) PL3362480T3 (pl)
RU (1) RU2707121C9 (pl)
TW (1) TWI615406B (pl)
WO (1) WO2017099362A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220275080A1 (en) * 2018-10-17 2022-09-01 Good T Cells, Inc. Binding molecule specific to lrig-1 protein, and use thereof
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0173281B1 (ko) 1996-11-30 1999-02-18 양재신 자동차의 램프 각도 조절장치
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EA022201B1 (ru) * 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US8895001B2 (en) * 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
BR112012025730B1 (pt) * 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
AU2012274461A1 (en) * 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
CA2849508C (en) * 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US11305012B2 (en) * 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof

Also Published As

Publication number Publication date
CN112472804A (zh) 2021-03-12
AU2016365506B2 (en) 2019-06-20
EP3778647B1 (en) 2026-02-25
WO2017099362A1 (en) 2017-06-15
JP6982574B2 (ja) 2021-12-17
RU2707121C9 (ru) 2020-06-16
BR112018006900A2 (pt) 2018-10-16
KR101746152B1 (ko) 2017-06-13
EP3362480A1 (en) 2018-08-22
US20180085455A1 (en) 2018-03-29
TW201726742A (zh) 2017-08-01
CA3000835C (en) 2020-06-09
JP2018536026A (ja) 2018-12-06
ES2891990T3 (es) 2022-02-01
RU2018113269A (ru) 2019-10-18
RU2018113269A3 (pl) 2019-10-18
JP6989645B2 (ja) 2022-01-05
EP3362480A4 (en) 2019-06-05
US10413607B2 (en) 2019-09-17
CN107683292A (zh) 2018-02-09
AU2016365506A1 (en) 2018-04-12
JP2020117512A (ja) 2020-08-06
CN112472804B (zh) 2024-07-23
EP3778647A1 (en) 2021-02-17
MX394911B (es) 2025-03-24
CN107683292B (zh) 2021-06-08
CA3000835A1 (en) 2017-06-15
AU2016365506A9 (en) 2018-11-01
MX2018004228A (es) 2018-05-15
AR107012A1 (es) 2018-03-14
EP3362480B1 (en) 2021-08-04
RU2707121C2 (ru) 2019-11-22
TWI615406B (zh) 2018-02-21

Similar Documents

Publication Publication Date Title
IL283321A (en) Antibodies against muc16 and their uses
ZA201903848B (en) Antibodies that specifically bind to human il-15 and uses thereof
ZA201906813B (en) Antibody binding specifically to muc1 and use thereof
IL258284A (en) Anti-Lag 3 antibodies and their uses
IL257263A (en) Antibodies against angptl8 and their use
SMT202600071T1 (it) Proteine leganti l'antigene anti-tl 1a e relativi usi
IL246921A0 (en) Binding proteins and their uses
ZA201808582B (en) Antibodies to alpha-synuclein and uses thereof
IL254954B (en) Anti-pacap antibodies and their uses
GB201519858D0 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
SG11201607109QA (en) Antibodies that bind egfr and erbb3
PL2992010T3 (pl) Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
SG11201505762XA (en) Il-11r binding proteins and uses thereof
IL247315B (en) Anti-acth antibodies and their uses
PL3292154T3 (pl) Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania
IL251676A0 (en) Antibodies that bind to ccr6 and their uses
IL266516B (en) An antibody that specifically binds to cd66c and its use
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
SG11201704500VA (en) Antibody binding to neuropilin 1 and use thereof
PL3362480T3 (pl) Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie
SG11202001813UA (en) Polypeptide and antibody bound to polypeptide
PL3233912T3 (pl) Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
PL3660052T3 (pl) Przeciwciało wiążące się swoiście z białkiem pauf i jego zastosowanie